相关实验视频
Updated: Jun 23, 2025
08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
Published on: August 31, 2016
15.2K
使用基于人口的描述性流行病学方法对异性造血细胞移植生存率的趋势:对国家移植注册数据的分析
Yachiyo Kuwatsuka1, Hidemi Ito2, Ken Tabuchi3
1Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan. ykuwatsuka@med.nagoya-u.ac.jp.
Bone marrow transplantation
|June 19, 2024
概括
血造细胞移植 (HCT) 存活率正在改善. 对HCT患者的长期生存分析显示,许多患者的条件生存率超过90%,这表明长期预后良好.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 移植医学 移植医学
背景情况:
- 造血细胞移植 (HCT) 的生存率正在改善.
- 短期生存指标可能无法完全捕捉患者的长期结果.
- 准确的长期预后评估对于HCT患者至关重要.
研究的目的:
- 用条件净生存率 (CS) 来评估长期存活率,用于大量HCT患者队列.
- 为了确定影响异构HCT后长期存活的因素.
- 建立长期HCT生存的基准.
主要方法:
- 利用了来自日本HCT注册的数据,其中包括41,716名第一个异性HCT接受者 (1991-2015).
- 使用Pohar-Perme方法计算的净生存率和5年条件净生存率 (CS).
- 按疾病,年龄组和移植来源分层生存率.
主要成果:
- 总体而言,10年净生存率为41.5% (男性) 和47.4% (女性).
- 对于大多数疾病,5年幸存者的5年CS超过了90%,除了骨髓质疏松症候群,多发性骨髓瘤和成人T细胞白血病/淋巴瘤.
- 无形性贫血患者的条件生存率,特别是接受带血的儿童和年轻人,超过了100%,表明寿命与一般人群相比较.
结论:
- 条件净存活率提供了一个比原始存活率更具信息性的衡量HCT后的长期预后.
- 大多数HCT幸存者表现出优秀的长期生存前景,特别是对于某些疾病,如无性贫血.
- 这些发现为评估HCT结果和比较国际注册表数据提供了有价值的基准.
更多相关视频
相关概念视频
01:22Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
01:20Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
01:21Hematopoiesis
5.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.2K
01:24Kaplan-Meier Approach
129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129
01:20Actuarial Approach
74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74